Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Regarding the role of F ENO in predicting failure after ICS reduction in mild-to-moderate asthma patients Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020 Year: 2020
Are there sub groups of children with asthma where FeNO guided treatment is associated with reduced risk for asthma attacks? Source: International Congress 2017 – Diagnostic tools in paediatric asthma Year: 2017
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Ex-smokers with frequent COPD exacerbations have low FENO in stable condition Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Additional value of spirometry in risk assessment of acute respiratory disease in winter among patients with mild to moderate asthma or COPD Source: Eur Respir J 2002; 20: Suppl. 38, 473s Year: 2002
Predictive value of spirometry trend and FeNO for difficult to treat asthma in children Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management Year: 2010
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018
Can seriousness of respiratory failure be predicted by the values of clinical score in patients with acute severe asthma? Source: Eur Respir J 2001; 18: Suppl. 33, 73s Year: 2001
Evaluation of pain pressure threshold in patients with moderate to severe symptomatic COPD and healthy controls Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020
Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005
Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005
Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005